











































Understanding Intra-Species and Inter-Species Prion Conversion
and Zoonotic Potential Using Protein Misfolding Cyclic
Amplification
Citation for published version:
Peden, AH, Suleiman, S & Barria, MA 2021, 'Understanding Intra-Species and Inter-Species Prion
Conversion and Zoonotic Potential Using Protein Misfolding Cyclic Amplification', Frontiers in Aging
Neuroscience, vol. 13. https://doi.org/10.3389/fnagi.2021.716452
Digital Object Identifier (DOI):
10.3389/fnagi.2021.716452
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Frontiers in Aging Neuroscience
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 22. Dec. 2021
fnagi-13-716452 July 28, 2021 Time: 13:35 # 1
REVIEW




University of Verona, Italy
Reviewed by:
Justin J. Greenlee,
National Animal Disease Center
(USDA ARS), United States
Christina Doriana Orru,
Rocky Mountain Laboratories (NIAID),
United States
Brent Race,





Received: 28 May 2021
Accepted: 07 July 2021
Published: 03 August 2021
Citation:
Peden AH, Suleiman S and
Barria MA (2021) Understanding
Intra-Species and Inter-Species Prion
Conversion and Zoonotic Potential
Using Protein Misfolding Cyclic
Amplification.
Front. Aging Neurosci. 13:716452.
doi: 10.3389/fnagi.2021.716452
Understanding Intra-Species and
Inter-Species Prion Conversion and
Zoonotic Potential Using Protein
Misfolding Cyclic Amplification
Alexander H. Peden, Suzanne Suleiman and Marcelo A. Barria*
National CJD Research & Surveillance Unit, Centre for Clinical Brain Sciences, Deanery of Clinical Medicine, The University
of Edinburgh, Edinburgh, United Kingdom
Prion diseases are fatal neurodegenerative disorders that affect humans and animals,
and can also be transmitted from animals to humans. A fundamental event in prion
disease pathogenesis is the conversion of normal host prion protein (PrPC) to a disease-
associated misfolded form (PrPSc). Whether or not an animal prion disease can infect
humans cannot be determined a priori. There is a consensus that classical bovine
spongiform encephalopathy (C-type BSE) in cattle transmits to humans, and that
classical sheep scrapie is of little or no risk to human health. However, the zoonotic
potential of more recently identified animal prion diseases, such as atypical scrapie,
H-type and L-type BSE and chronic wasting disease (CWD) in cervids, remains an open
question. Important components of the zoonotic barrier are (i) physiological differences
between humans and the animal in question, (ii) amino acid sequence differences
of the animal and human PrPC, and (iii) the animal prion strain, enciphered in the
conformation of PrPSc. Historically, the direct inoculation of experimental animals has
provided essential information on the transmissibility and compatibility of prion strains.
More recently, cell-free molecular conversion assays have been used to examine the
molecular compatibility on prion replication and zoonotic potential. One such assay is
Protein Misfolding Cyclic Amplification (PMCA), in which a small amount of infected
tissue homogenate, containing PrPSc, is added as a seed to an excess of normal
tissue homogenate containing PrPC, and prion conversion is accelerated by cycles
of incubation and ultrasonication. PMCA has been used to measure the molecular
feasibility of prion transmission in a range of scenarios using genotypically homologous
and heterologous combinations of PrPSc seed and PrPC substrate. Furthermore, this
method can be used to speculate on the molecular profile of PrPSc that might arise
from a zoonotic transmission. We discuss the experimental approaches that have been
used to model both the intra- and inter-species molecular compatibility of prions, and
the factors affecting PrPc to PrPSc conversion and zoonotic potential. We conclude that
cell-free prion protein conversion assays, especially PMCA, are useful, rapid and low-
cost approaches for elucidating the mechanisms of prion propagation and assessing
the risk of animal prions to humans.
Keywords: neurodegenarative disease, prion, CJD (Creutzfeldt-Jakob disease), protein misfolding, in vitro
aggregation assays, surveillance, zoonosis, prion diseases
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OVERVIEW
Prion
Prions – Proteaceous infectious particles- are self-propagating
structures identified as the major or sole cause of prion
diseases, which are lethal neurodegenerative disorders that affect
animals and humans. The pathogenesis of prion diseases is
strongly believed to be related to protein misfolding. The
normal prion protein, PrPC, encoded by PRNP, is a highly
conserved cell surface glycoprotein. It is thought to have a
number of physiological roles in both the central and peripheral
nervous system and may serve as a regulatory protein in
cell proliferation and differentiation (Halliez et al., 2014; Wulf
et al., 2017). In prion disorders, PrPC is believed to change its
conformation and become misfolded. The abnormal misfolded
version, PrPSc, is partly resistant to proteinase K and can
self-reproduce by causing PrPC to convert to its abnormal
isoform. The resultant misfolded molecules form multi-chain
fibrillary/amyloid aggregates. Over months to several years
in vivo, these structures accumulate in brain and nerve tissue,
triggering cell death and the neurodegeneration associated
with prion diseases (Prusiner, 1982; Ironside et al., 2014;
Love et al., 2015).
Animal and Human Prion Diseases
Animal prion diseases include bovine spongiform
encephalopathy (BSE) in cattle, scrapie in sheep and goats,
transmissible mink encephalopathy (TME) and chronic wasting
disease (CWD) in several cervid species, including, elk,
moose, and reindeer or caribou (Sigurdson and Aguzzi, 2007).
More recently, a novel type of prion disease was reported in
dromedary camels (Babelhadj et al., 2018). In humans, prion
diseases are clinically and pathologically heterogeneous, and
can present as either (1) spontaneous disorders, e.g., sporadic
CJD (sCJD) and variably protease-sensitive prionopathy
(VPSPr); (2) genetic disorders, including Gerstmann-Sträussler-
Scheinker disease (GSS) and genetic CJD (gCJD) (Richt and
Hall, 2008); (3) and acquired/transmissible forms, such as
variant CJD (vCJD), iatrogenic CJD (iCJD) and kuru. The
transmissible neurodegenerative diseases caused by prions
are also known collectively as “transmissible spongiform
encephalopathies” or TSEs.
Prion Strains
Currently, the protein-only hypothesis remains the most
accepted paradigm in prion research. In this model, prions are
transmissible particles that are devoid of nucleic acid and seem
to be composed entirely of a modified disease-associated form
of the prion protein (PrPSc) (Griffith, 1967; Prusiner, 1982). In
this model PrPSc self-propagates by conversion of PrPC and is
able to infect new individuals and sometimes, as in BSE, is able
to transmit to a different species. However, PrPSc still resembles
other conventional infectious agents by expressing characteristic
strain variations; i.e., a particular prion strain can encode one
of various specific disease phenotypes that are maintained after
inoculation and serial passage in experimental animals. It was
initially assumed that the strain phenomenon might be a function
of the PrPC primary structure of the host. However, different
prion strains were also identified in genetically identical mice
suggesting that strain variation is not simply dependent on
amino acid similarities between donor and recipient (Collinge
and Clarke, 2007). According to the protein-only hypothesis
the strain-specific properties are enciphered in the various
conformations that PrPSc can adopt and are maintained when
PrPSc replicates through conversion of PrPC (Griffith, 1967;
Prusiner, 1982).
Prion diversity has historically been investigated by
experimental transmission studies in animal models, where
several criteria, including the length of time between inoculation
and appearance of clinical signs, the type of clinical signs,
neuropathological changes (score profile) and biophysical
measures can be measured (Brandner and Jaunmuktane, 2017;
Igel-Egalon et al., 2018). The classical way of biochemically
classifying prion diversity is by PrPSc proteolysis and studying
the biochemical profile of the protease resistant core on western
blot analysis. Three major bands are usually observed upon
cleavage with proteinase K, corresponding to un-, mono- and
di-glycosylated forms of PrP. The size and relative abundance of
these three forms is usually characteristic of a particular prion
variant, referred to as the PrPres subtype (Head and Ironside,
2012). In the classification of human prion disease subtypes using
the nomenclature of Parchi (Parchi et al., 2012), unglycosylated
bands at 21 or 19 kDa are associated with PrPSc types 1 and 2,
respectively. In addition, a predominance of either the mono- or
di-glycosylated band is assigned as type A and B, respectively. All
sporadic CJD cases are of the ‘A’ glycoform and are either type
1 or 2, whereas variant CJD is associated with type 2B. These
differences in fragment size and glycosylation ratios are believed
to be associated with different PrPSc conformations, which are in
turn associated with different prion strains.
Polymorphic differences clearly play a key role in influencing
prion strains in human prion disease. It is well-recognized that
codon 129 of the prion protein gene PRNP, which has either
methionine (M) or valine (V), correlates with the molecular
typing and prion strain characteristics (Love et al., 2015). The
strain phenomenon is observed in sporadic forms of prion
disease. Sporadic CJD Type 1 subtype is favored in individuals
who are methionine homozygous (MM) at polymorphic codon
129 of PRNP, whereas valine homozygosity at this codon favors
Type 2. MV heterozygous individuals with sCJD are more evenly
split between Type 1 and Type 2 (Parchi et al., 1999). The
association of sCJD subtypes with strains was supported by
transmission studies to transgenic mice expressing human PRNP
(TgHu) with the three PRNP codon 129 genotypes (MM, MV,
and VV), which suggested the existence of four prion strains
(M1, M2, V1, and V2), and a fifth strain corresponding to
a thalamic sub-subtype, MM2T, also known as sporadic fatal
insomnia (Bishop et al., 2010; Moda et al., 2012). However, the
example of sCJD subtypes alludes to the existence of an overlap
between prion strains, with the commonly observed co-existence
of more than one PrPSc subtype within individual sCJD patients
(Polymenidou et al., 2005; Uro-Coste et al., 2008; Cali et al., 2009;
Parchi et al., 2009).
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Conformation Selection Theory
In light of evidence that prion strains may not be absolutely
discreet entities, Collinge and Clarke (2007) proposed a
conformation selection theory in which a prion strain is thought
to be comprised of not just one type of PrPSc molecular assembly,
but instead a range or cloud of assemblies with different tertiary
and quaternary structures. In this model, a subset of assemblies
within this cloud may be selected for replication in a new
individual of the same species with an alternate PRNP genotype,
or in a new species. The transmission will occur more readily
if a significant subset of conformers of the prion strain can
successfully replicate in the new host, and this will be determined
in part by the compatibility of the PrP sequence.
Development of in vitro Models as
Versatile and Reproducible Alternatives
to Investigate Prion Diseases
Evaluation of transmission barriers using the in vivo models
requires the use of large numbers of experimental animals.
In addition, despite the development of the transgenic animal
models, the speed with which animal research can be conducted
has been hindered by long incubation periods, especially when
serial passage is being used to evaluate prion strain stabilization
or adaptation. Therefore, there has been an urgent need to
develop alternative, quicker, more cost-efficient and reliable
in vitro models.
The first in vitro cell-free system for modeling prion
conversion was demonstrated by Kocisko et al. (1994). They
showed that the radiolabeled recombinant hamster PrPC was able
to selectively convert to its PK-resistant PrPSc isoform in the
presence of unlabeled hamster PrPSc. This conversion occurred
even after de-glycosylation of PrPSc or transient denaturation
with a chaotropic agent (GdnHCl) (Kocisko et al., 1994).
Protein Misfolding Cyclic Amplification
(PMCA)
A few years later, Saborio et al., 2001 successfully established a
procedure that applied cycles of incubation and sonication to
efficiently accelerate the conversion of PrPC in a hamster brain
homogenate by hamster PrPSc. The process was named Protein
Misfolding Cyclic Amplification, or PMCA (Saborio et al., 2001;
Figure 1). In the seeding phase of PMCA, an excess amount
of PrPC (termed the substrate) is seeded with small quantities
of PrPSc (termed the seed). During the amplification phase, the
mixture is incubated at 37◦C and the PrPSc seed induces the
generation of large PrPSc aggregates at the expense of PrPC
(Figure 1). PMCA thus mimics the natural propagation of PrPSc
and its aggregation in the brains of TSE-infected individuals.
In order to increase amplification efficiency, ultrasound power
is applied periodically to break down these large misfolded
aggregates and produce more of the active converting units,
which accelerates the reaction in an exponential manner. By the
end of one round of PMCA, most molecules are present in their
misfolded conformation and PrPSc becomes detectable. In the
detection phase of PMCA, the amplified product is detected,
usually by western blotting following limited proteolysis to detect
FIGURE 1 | Protein misfolding cyclic amplification (PMCA). PMCA reaction
mix is composed of minute amounts of the misfolded abnormal β sheet-rich
prion protein (seed PrPSc) and a large excess of the normal α-helix prion
protein (substrate PrPC), in addition to reaction cofactors such as
ethylenediaminetetraacetic acid (EDTA) and heparin as reported for some of
the established protocols (Barria et al., 2014b, 2018a; Ritchie et al., 2017).
The PMCA reaction mimics the in vivo PrP conversion; i.e., according to the
template-directed model of propagation, when incubated at 37◦C, PrPSc
interacts with PrPC and thereby alters its conformation. The newly formed
misfolded subunits grow and aggregate to form large fibrillary structures.
Ultrasonication is applied to break down the misfolded aggregates into active
converting “seeds” that lead the reaction again in a cyclic manner. By the end
of one 48-h round of PMCA, most PrPC molecules are converted into its
misfolded form, enabling their subsequent detection by western blotting.
the protease resistant fragments of PrPSc (PrPres) (Figure 2).
Several studies that followed the original demonstration of
PMCA indicated the flexibility, fidelity and reliability of this
method. PMCA was shown to reproduce the infected agent
in vitro by serially repeating the amplification round on the
diluted product (Castilla et al., 2008b, 2005). The infectivity per
unit of PMCA PrPSc was comparable to that of PrPSc from
the infected tissue used as the seed (Castilla et al., 2005). The
serially amplified product, which becomes devoid of the original
seed, was shown to hold a comparable secondary structure,
electrophoretic mobility and glycosylation profile to that of the
seed (Castilla et al., 2005). Moreover, strain-specific infectivity
was revealed to be conserved within the amplified product when
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FIGURE 2 | Protein misfolding cyclic amplification and its three technical phases. In designing a PMCA experiment there are three phases to consider, which each
involve decisions depending on the research question and resources available. In the seeding phase, a minute amount of PrPSc seed (small green circle) is mixed
with an excess of PrPC substrate (large brown circle). For both these components, the species, PRNP genotype, and tissue source need to be chosen. In addition,
the prion strain of the seed needs to be selected. In the amplification phase, cofactors may be added to the above mixture which is then subjected to cycles of
incubation and sonication. Choices are required for the physical parameters (e.g., cycle time, incubation versus sonication time per cycle, number of cycles, and
amplitude of ultra-sonication). In the detection phase, the amplified product is quantified and/or characterized, usually by western blotting following limited protease
digestion. Cross-species amplification can be confirmed with species-specific detection antibodies, whereas alterations in the PrPres molecular profile can be
confirmed with subtype-specific antibodies.
four mouse-adapted scrapie (RML, ME7, 139A, 79A), one mouse
adapted BSE (310C) and four human prion disease (vCJD, sCJD
MM1, sCJD MM2, sCJD VV2) PMCA-propagated strains were
inoculated into experimental animals. Indeed, after serial rounds
of PMCA, the PMCA-amplified product caused a comparable
disease phenotype in experimental animals (incubation time,
clinical signs and neuropathological profile) as the original seed
(Castilla et al., 2008b; Cali et al., 2019). Thus, the characteristics
of the original strain used as seed seems to be still encoded within
the PMCA amplified product, providing fundamental proof that
the strain characteristics, including infectivity, are preserved after
in vitro amplification. In only a few weeks this technique can
replicate PrPSc and conserve prion strain properties in a manner
that recapitulates the time-consuming in vivo approach that
might take several years.
The development of in vitro conversion assays, such as
PMCA, opened a new era in prion research. In time,
improvements in the sensitive of PMCA allowed the detection
of extremely low levels of PrPSc in peripheral tissues and
biological fluids in human samples (Moda et al., 2014;
Bougard et al., 2016, 2018; Concha-Marambio et al., 2016; Barria
et al., 2018a; Concha-Marambio et al., 2020).




As mentioned before, in humans, prion strain variation and
the polymorphic codon 129 of PRNP are two of the major
biological determinants of the clinicopathological phenotype of
the disease and an individual’s susceptibility to develop prion
diseases. PRNP polymorphism imposes its effect by altering prion
strain conformation. Empirical evidence for this came from
Parchi et al. (2000) who showed that codon 129 is a primary
determinant of the proteinase cleavage site of PrPSc in CJD,
resulting in a change in the size of the PrP proteinase resistant
fragments (Parchi et al., 2000).
Although allelic variation percentages for this codon vary
across different ethnic groups, homozygosity of methionine is a
major risk factor in all CJD types (Deslys et al., 1998). Indeed,
with the exception of one case, all clinical and pathologically
confirmed vCJD cases, including three cases of secondary vCJD
following blood transfusion, have had an MM genotype at codon
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129. The exception is the last reported United Kingdom case that
was MV at codon 129 (Mok et al., 2017). Similarly, susceptibility
to sCJD is considerably higher in methionine homozygous
individuals (Palmer et al., 1991). In addition, sporadic CJD
patients who are codon 129 heterozygous have longer durations
of disease (Pocchiari et al., 2004).
To shed more light on the role of codon 129 polymorphism
on prion strain characteristics and transmissibility, Jones et al.,
2007 recapitulated the transmission properties of vCJD and sCJD
in two important PMCA studies. The first employed PMCA to
model secondary vCJD transmission in humans (Jones et al.,
2007). This study used either healthy human brain tissues or
humanized transgenic mice models expressing the three possible
codon 129 genotypes (MM, MV, and VV). Interestingly, vCJD
propagated efficiently in both MM substrates, supporting the idea
that codon 129 has a strong influence on PrPSc conversion and
infectivity. Less amplification was observed in MV2 transgenic
mouse brain tissues, while no amplification was observed in
VV substrates, which suggested that this genotype might be a
protective factor.
This study emphasized the impact of PRNP codon 129
genotype on susceptibility to human-to-human transmission of
vCJD and indicated that MM imposes a higher risk than the other
two genotypes. MV individuals still have some risk of developing
vCJD and might remain asymptomatic for long periods before
developing clinical disease.
The second PMCA study by Jones et al. used (MM/MV/VV)
homogenates as substrates and six sCJD disease PrPSc seeds
representing the six phenotypic subtypes based on subtype and
codon 129 genotype: MM1/MV1, VV1, MM2 cortical, MM2
thalamic, MV2 and VV2 (Jones et al., 2008). As with vCJD,
the results indicated that PMCA was an attractive model for
investigating the molecular basis of phenotypic variability in
sCJD. A considerable degree of compatibility in terms of the
PrPSc subtype was observed between the sCJD seed and the
PMCA product. Here too, codon 129 polymorphism was shown
to have an impact on amplification efficiency, which reflected
the relationship observed between PrPSc subtype and codon
129 genotype in sCJD patients. Successful amplification was
recorded when seed and substrate codon 129 polymorphisms
were matched. Remarkably, MV1 resembled MM1 as it tended
to amplify better with MM substrate, whereas MV2 preferred VV
substrate. Therefore, the substrate specificity of PrPSc from MV
sCJD patients appeared to depend on PrPSc type.
Iatrogenic Creutzfeldt-Jakob Disease:
Molecular Approaches
Acquired forms of CJD caused by prion infection as a result
of medical or surgical interventions are collectively referred
as iatrogenic CJD (iCJD). Apart from secondary transmission
of vCJD via blood or blood products (Peden et al., 2004;
Urwin et al., 2016), iCJD also includes cases acquired by the
use of contaminated medical instruments (Bernoulli et al., 1977;
Will and Matthews, 1982), transplantation of contaminated
corneal grafts (Duffy et al., 1974), cadaveric dura mater (DM-
iCJD) (Brown et al., 2012), or treatment with contaminated
cadaveric growth hormone (GH-iCJD) (Gibbs et al., 1985; Koch
et al., 1985; Powell-Jackson et al., 1985; Ritchie et al., 2017).
DM-iCJD and GH-iCJD comprise the majority of iCJD cases
worldwide (Brown et al., 2012; Ritchie and Barria, 2021).
The PRNP codon 129 genotype affects susceptibility and
disease phenotype in iCJD. Surveillance studies on a French
cohort indicated that the majority of the GH-iCJD cases
were codon 129 methionine homozygous (Delisle et al., 1993;
Brandel et al., 2003). In contrast, where codon 129 data
is available most United Kingdom cases of iCJD are either
heterozygous (MV), or valine homozygous (VV) and only
a low proportion ∼10% were homozygous for methionine
(MM) (Brandel et al., 2003; Rudge et al., 2015; Ritchie et al.,
2017). This suggests that original sources of contamination for
the United Kingdom and French GH-iCJD epidemics were
of different prion strains. The MM cases tended to occur
later in United Kingdom GH-iCJD epidemic, suggesting a
longer incubation period for patients with this genotype, which
may indicate a genotypic barrier in these individuals to the
contaminating prion strain. Alternatively, the MM cases may be
the result of infection from a minor component of a mixture of
contaminating strains.
Although the use of cell-free assays to model iatrogenic
CJD is limited, PMCA was used in combination with other
biochemical analyses to investigate the prion strain origin of the
United Kingdom GH-iCJD epidemic, and the possibility that
MM GH-iCJD cases might exhibit the traceback phenomenon
(Ritchie et al., 2017).
Traceback Phenomenon
The traceback phenomenon was observed in animal research
studies when sCJD brain inocula of V2 strain was transmitted
to humanized mice MM at PRNP codon 129 (Kobayashi
et al., 2007). This transmission resulted in a new strain
characterized by a unique disease phenotype featuring long
incubation periods, and kuru-like plaques on histological
examination. In addition, this strain was associated with
an altered PrPSc conformation that caused the appearance
of an upshifted proteinase-resistant unglycosylated band at
∼20 kDa on western blots, referred to as intermediate
PrPSc (PrPSc subtype i). When this strain was inoculated on
second passage into TgHu VV mice, the PrPSc appeared to
regain its original conformation, resulting in type 2 PrPSc
(Kobayashi et al., 2007). This property suggests that the new
strain (PrPSc i) still retains within its conformational cloud
some traits from the original V2 strain that are “inherited,”
which means that when transmitted into new animals it
can express its original strain characteristics once again
(Kobayashi et al., 2009, 2010).
PMCA Investigation of Traceback
Phenomenon
Two PMCA methods have been used to investigate the
traceback phenomenon. Takeuchi et al. (2016) utilized cell-
PMCA (where the PrPC source was from a 293F cell-lysates,
overexpressing the human form of the prion protein) to
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amplify brain homogenate samples from two DM-iCJD cases,
both MM at codon 129 in Japan. The cases considered for
the study included a case of non-plaque-type DM-iCJD (np-
dCJD) resembling sCJD MM1/MV1, while the other case was
plaque-type DM-iCJD (p-dCJD) characterized by kuru plaques
and PrPSc with an intermediate type (PrPSc subtype i). The
p-dCJD PrPSc material presented molecular compatibility when
a substrate homozygous for valine, not methionine, was used.
The amplified material resembled the sCJD V2 strain biochemical
typing. These results appear to defy the expected relationship
between PMCA efficiency and the genotype compatibility of
seed and substrate. The authors suggested this was evidence
that plaque-type DM-iCJD was the result of transmission
of the V2 CJD strain to codon 129 MM patients, and its
efficient amplification in VV substrate was an indication of the
traceback phenomenon.
Ritchie et al. (2017) utilized several approaches to model 21
United Kingdom cases of GH-iCJD and three cases of DM-
iCJD. In particular, the authors were interested in two GH-
iCJD cases homozygous for methionine at codon 129: One
featured the plaque subtype and had PrPSc type i (subtype
MMi), whereas the other was of type 1 and had no plaques
(subtype MM1). Samples of cerebral cortex tissue from these
cases were used to seed humanized transgenic mouse brain
substrate carrying the codon 129 MM and VV. These two
MM GH-iCJD cases gave divergent results. For the MMi case
amplification was observed with the valine, not the methionine,
homozygous substrate, whereas the MM1 cases failed to amplify
efficiently with either substrate. More importantly, the molecular
strain typing profile of the amplified product of the VV
substrate seeded with MMi showed a downshifted migration
of the proteinase-resistant unglycosylated form by western
blotting when compared to the original material. In contrast
when MM substrate was used to amplify PrPSc from the
MMi case, an upshift occurred. The amplification of MMi
PrPSc with VV substrate and the downshift of the molecular
profile is possibly indicative of the traceback phenomenon
mentioned earlier; i.e., it may provide indirect evidence that
the MMi subtype results from the replication V2 strain in a
genotypically mismatched methionine homozygous individual
and that this subtype readily reverts to a downshifted, type 2-
like molecular profile when provided with a suitable VV substrate
for replication.
Both studies strongly indicated that PMCA is a rapid and
reliable method for modeling the molecular mechanisms of
prion transmission across genotypic barriers and the traceback
phenomenon. It would appear to be possible to identify DM-
iCJD cases in MM individuals that actually originated from
contamination with the V2 sCJD strain, rather than the M1
strain. Additionally, Kobayashi et al. (2016) have suggested that
kuru plaque pathology and PrPSc type i in codon 129 MM
patients diagnosed with sCJD may actually indicate an acquired
or iatrogenic etiology in these patients. Therefore, PMCA could
help ascertain the acquired origin of atypical sCJD cases, without
having actual evidence of iatrogenic exposure by examining the
potential for PrPSc amplification using matched and mismatched
humanized substrates (PRNP codon 129 MM or VV).





The species barrier refers to the combined factors that limit the
ability of a pathogen from one species to cross-infect another
species. Zoonotic potential refers to the likelihood this barrier
might be breached to infect humans. When examining the barrier
that may exist between two species for the transmission of a
given prion strain, the species from which the prion strain
originates can be considered to be the species of origin. The
species whose threat is being assessed (e.g., humans) is the target
species. Any other species through which the prion strain might
pass between the species of origin and the target species is an
intermediate species.
Zoonotic Prion Disease Threats to
Humans
Bovine spongiform encephalopathy is a prion disease of cattle,
first recognized in 1986 in the United Kingdom, reaching
epidemic proportions and then being brought under control
(Hope, 2013). Dietary exposure to BSE is thought to be the cause
of vCJD in humans (Will et al., 1996; Bruce et al., 1997; Hill et al.,
1997). The classical form of BSE (also known as C-type BSE, to
distinguish it from atypical forms) is therefore currently the only
known zoonotic prion disease described.
Scrapie is a prion disease of sheep, endemic in many countries
including the United Kingdom, which comprises several distinct
strains (Greenlee, 2019). There is polymorphic variation in the
sheep PRNP at amino acid positions 136, 154, and 171 that
affects susceptibility to scrapie, and the VRQ, ARQ, and ARR
genotypes have the greatest effect in this regard (Goldmann, 2008;
Gonzalez et al., 2012). Depending on the infecting source or
strain, VRQ/VRQ and ARQ/ARQ sheep are the most susceptible
to classical scrapie, whereas ARR/ARR is effectively resistant
(Hunter and Bossers, 2006). Although scrapie has been known
to exist for more than 200 years, in stark contrast to BSE, there is
no epidemiological evidence to suggest is poses a threat to human
health (Brown, 1998; van Duijn et al., 1998).
A longstanding question is whether BSE can pose a zoonotic
threat to humans via sheep. When considering zoonotic potential
from animal prion diseases to humans as the target species, the
risk posed by BSE from cattle as the species of origin is well
known. It remains unknown whether the United Kingdom sheep
flock was exposed to BSE early in the BSE epidemic, and whether
BSE could propagate and adapt in sheep to resemble scrapie
but retain its zoonotic potential for infecting humans. However,
various experimental approaches have been taken to model this
scenario as described below.
BSE in Sheep
Although no natural cases of BSE in sheep have been
detected, sheep can be experimentally infected with BSE
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(Foster et al., 2001), and it had been suggested that the clinical
signs of scrapie and sheep-BSE are clinically indistinguishable
(Stack et al., 2006) and that these forms of prion disease
could only be differentiated by careful immunohistochemical
examination and biochemical analysis of the protease resistant
PrPSc in the central nervous system of affected animals (Jeffrey
et al., 2001; Gonzalez et al., 2003; Thuring et al., 2004). It
is therefore possible that adaptation of the BSE agent to an
ovine host involves a change in the molecular properties of the
BSE prions and that this change may have occurred prior to
the introduction of statutory testing of sheep for scrapie. An
important concern is whether sheep-adapted BSE would retain
the potential to infect humans, or indeed be more virulent
(Espinosa et al., 2007; Plinston et al., 2014).
Using Serial PMCA to Assess the
Zoonotic Risks
Many transmission studies have investigated the potential of BSE
to infect sheep (Foster et al., 2001; Gonzalez et al., 2003; Stack
et al., 2009), and for sustained transmission of BSE in flocks
(Bellworthy et al., 2005; Jeffrey et al., 2015), and the potential for
BSE-infected sheep to infect humans (Plinston et al., 2014; Joiner
et al., 2018). As mentioned previously, a disadvantage of these
in vivo investigations is that they are often lengthy and expensive.
The in vitro conversion assay, PMCA, provides an alternative
means for investigating species barriers and for specifically
examining the molecular feasibility of zoonotic transmissions.
In the serial automated PMCA (saPMCA), the product from
one round of PMCA is used to seed fresh PrPC substrate in
successive rounds of PMCA performed in series (Castilla et al.,
2005, 2006) (Figure 3). By providing fresh PrPC substrate with
each round, saPMCA overcomes a major limitation of PMCA
which is the thermolability of PrPC at 37◦C and thereby extends
the amplification process. Therefore, saPMCA can be used to
investigate whether the propagation of a prion strain with
PrPC substrate from another species is possible and moreover
whether in can be sustained (Castilla et al., 2005; Krejciova et al.,
2014). Serial automated PMCA can also be used to investigate
whether the propagation of a prion strain from the species
of origin via an intermediate species modifies its potential for
infecting and propagating in the target species in question,
for example humans.
Investigating Whether a Prion Strain Can
Be Continuously Propagated in vitro
The potential for BSE prions to be continuously propagated in
sheep was investigated by saPMCA. Using sheep ARQ/ARQ PrPC
as a substrate, Krejciova et al. (2014) showed that BSE from
cattle, or experimentally challenged sheep, could be continuously
amplified over at least eight rounds. The PrPSc subtype was
unaltered, suggesting a conservation of the BSE agent strain
using this substrate. These findings agreed with an animal
transmission study showing BSE prions could be serially passaged
three times through sheep of the ARQ/ARQ genotype, with
only minor alternations of the molecular properties of PrPSc
(Stack et al., 2009). In contrast, PrPC from ARR/ARR sheep, a
genotype known to be more resistant to scrapie, could not sustain
the amplification of cattle or sheep BSE PrPSc over successive
rounds (Krejciova et al., 2014), even though amplification of
sheep BSE PrPSc was observed for seeds in the first round.
Modeling Strain Adaption
In addition to testing for sustainable prion propagation, saPMCA
can also be used to investigate whether the properties of the strain
are modified and to explore the possibility of strain adaption in
either an intermediate species or the target species. Alterations
in the molecular profile of the PrPSc amplified product can be
used as indicator of changes to agent strain (Castilla et al., 2008a).
In most cases these will be changes in the molecular mass of
the unglycosylated fragment or the relative intensities of the di-,
mono- and unglycosylated fragments, which can be monitored by
analyzing samples of the saPMCA rounds by western blotting.
Changes in the molecular subtype that arise during saPMCA
can also be detected using PrPSc subtype-specific antibodies. For
instance, when sheep BSE was propagated using ovine VRQ/VRQ
substrate by saPMCA, the generic anti-PrP 6H4 monoclonal
antibody detected an upward shift to more scrapie-like molecular
profile in the latter rounds. This was further verified using the
12B2 monoclonal antibody, which specifically detects the longer,
slower migrating protease resistant PrPSc fragment associated
with scrapie (Krejciova et al., 2014). This indicates a possible
strain adaptation that might occur in vivo if BSE infection spread
into a sheep population.
This was not the first study to show that saPMCA could model
the process of strain adaptation. For instance, Green et al. (2008)
demonstrated that saPMCA could enable mouse prions of the
RML strain to adapt to replication using deer PrPC. When RML
prions were propagated using cervid PrPC expressed in TgCer
mice the physiochemical properties and western blot profile of
PrPSc were altered, and there was an increased ability to infect
TgCer mice resulting in a prion strain with unique properties
(Green et al., 2008).
Mechanisms of Strain Adaption
The mechanism by which prion strain adaptation occurs in vitro
or in vivo is still at matter of debate. The shift in the molecular
profile observed after multiple rounds of saPMCA using PrPC
from a different species as substrate is compatible with the idea
that the strain of origin, such as BSE, might comprise a molecular
cloud of conformers. When a prion strain is introduced into
the target or intermediate species, a subset of conformers is
selected for amplification (Collinge and Clarke, 2007; Krejciova
et al., 2014; Collinge, 2016). In this model, if a large subset of
conformers of the original prion strain can replicate in the target
species, the species barrier will be low. The size of the subset
of conformers that can replicate in both species will partly be
determined by the primary structure of PrP from both species.
An alternative but not mutually exclusive model is
described as “deformed templating.” In this model, when a
prion strain is introduced into a new species, PrP primary
structural differences between the species impose molecular
constraints that force the generation of a range of new PrPSc
variants (Makarava and Baskakov, 2012; Makarava et al., 2013;
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FIGURE 3 | Investigating inter-species transmissibility by PMCA and saPMCA. The potential for a prion strain to cross the species barrier between the species of
origin (dark green) and the target species (brown) can be assessed by a single round PMCA experiment. Alternatively, in serial automated PMCA (saPMCA), the
amplification phase can be extended by multiple rounds in which the seed from one round is diluted into fresh PrPC substrate. Multiple rounds of saPMCA using
PrPC from the species of origin might stabilize a prion strain to increase inter-species transmissibility. Alternatively, saPMCA with target species PrPC could be used
to examine the potential for a strain to adapt to a new replication environment. Finally, saPMCA can be used to address whether propagation with PrPC from an
intermediate species (light green) facilitates transmission to the target species.
Baskakov, 2014). One of these variants may prove to be
particularly adept at replication in the new host, resulting in
the emergence of a new strain. With either model, PMCA and
saPMCA are capable of modeling strain adaptation, regardless
of the mechanism.
The conformational selection or deformed templating models
are consistent with the findings of Huor et al. (2019) who
used both animal transmission studies and saPMCA to show
evidence of a C-type BSE-like signature emerging from atypical
scrapie. When atypical scrapie PrPSc seeds were amplified
over several rounds of saPMCA using TgBov substrate, PrPSc
with a BSE-like molecular profile was amplified, that could
be clearly discriminated from scrapie-like PrPSc using PrPSc
subtype specific antibodies. These results indicated the theoretical
possibility that classic BSE might arise through cross-infection
from atypical sheep scrapie. In this way PMCA can amplify
subsets of these molecular clouds that point to the existence of
minority strains that may exist within other strains. In this way,
PMCA and saPMCA may offer insights into the provenance of
certain prion strains.
Zoonotic Threat After Strain Adaptation
in an Intermediate Species
An advantage of saPMCA is that amplification protocols can be
concatenated, i.e., the end-product of one amplification protocol
can be used to seed further amplification using substrate from
an individual with a different genotype, or another species
entirely (Figure 3). This approach is useful for investigating
whether an animal prion disease becomes a threat to human
health after cross-infection and propagation in an intermediate
species. Humanized transgenic mouse brain (TgHu) expressing
the three polymorphic genotypes of PRNP codon 129 (TgHuMM,
TgHuMV, TgHuVV) have been commonly used as a PMCA
substrate to examine the zoonotic threat posed by animal prion
diseases (Barria et al., 2014b).
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The species-specificity of certain anti-PrP antibodies has
been used to evaluate the effect of in vitro studies of zoonotic
potential. These antibodies specifically detect the conversion
of the substrate PrPC to protease resistant PrPSc without
interference from the small amount of PrPSc that was added as
seed. For example, 3F4 recognizes the 106-112 epitope in human,
but not ovine or bovine PrP.
Krejciova et al. (2014) used 3F4 to show that C-type BSE
from cattle or experimentally infected sheep could induce the
conversion of human PrPC to PrPSc in single-round PMCA.
BSE PrPSc that had retained its BSE-like molecular signature
after amplification using an ARQ/ARQ ovine substrate also
retained its ability to convert human PrPC. In both cases,
conversion was dependent on the codon 129 genotype of human
PrP being MM. However, BSE PrPSc that had adapted and
acquired a scrapie-like molecular signature after amplification
using VRQ/VRQ substrate had lost its ability to convert
human PrPC. This experimental observation may suggest that
BSE PrPSc can adapt and adopt the guise of a scrapie-
like strain in sheep, but this adaptation reduces its zoonotic
threat to humans.
The effects of the adaption of BSE PrPSc to sheep on its
virulence toward humans have also been analyzed by animal
transmission studies. Padilla et al., 2011 showed that BSE prions
from cattle could infect TgHu mice that over-express PrPC MM
at codon 129, albeit with a large transmission barrier. This
barrier was significantly reduced when the same mouse models
were challenged with PrPSc from BSE-infected sheep and goats
suggesting an increased zoonotic threat from BSE in these species
(Padilla et al., 2011). However, it is not known what effect
adaptation of BSE prions to sheep or goats by multiple passages
would have on its virulence toward humans.
Emergent and Atypical Animal Prion
Diseases
Assessing the Zoonotic Threat of CWD and Atypical
Forms of Scrapie and BSE
The zoonotic threat to humans of BSE in cattle is well known.
In contrast, there is no epidemiological evidence to support
scrapie in sheep posing a risk to human health (Brown et al.,
1987; van Duijn et al., 1998). The zoonotic threat of CWD in
cervids, and atypical forms of both scrapie and BSE are unknown.
However, a number of in vitro and transmission studies using
TgHu mice or non-human primates suggest a significant barrier
for CWD transmission to humans [see Table in Barria et al.
(2014a) for a summary of the in vitro and in vivo approaches
that have been used]. Furthermore, challenge of TgHu mice with
atypical H- and L-type BSE, showed that L-type BSE is capable of
transmitting disease to transgenic mice overexpressing a human
PrP (Beringue et al., 2008).
Transmission studies using mice expressing human PrP, or
non-human primates, provide a rigorous assessment of the
zoonotic threat to humans posed by animal prion diseases
(Brandner and Jaunmuktane, 2017). However, this approach is
often slow and expensive. In contrast, in vitro conversion assays
such as PMCA are fast and adaptable. They can be used to
assess the potential for the heterologous conversion of human
PrP by newly emerging animal prion diseases, or atypical forms
of classic animal prion diseases. The approach of testing seeds
from multiple species in parallel against substrate from one
species (e.g., human) allows the zoonotic potential of several
prion strains to be compared. The results of these experiments
can be judged alongside evidence from epidemiology and
transmission studies.
An interesting observation of many of these comparisons is
the concept of conversion efficiency as a possible measure of
zoonotic potential, which can be inferred from the levels of PrPSc
that have accumulated after a defined period of amplification. In
this regard, the reliability of PMCA for modeling transmission
barriers has been evaluated by Levavasseur et al. (2014).
Using vCJD and atypical BSE seeds against various transgenic
mouse brain substrates, a good agreement between the
amplification factors obtained by PMCA results and attack
rates for parallel in vivo transmission experiments was observed
(Levavasseur et al., 2014).
Chronic wasting disease is an acquired prion disease of cervids
that affects captive and free-ranging deer and elk populations
primarily in North America but recently reported in Europe
(Sigurdson and Aguzzi, 2007; Benestad et al., 2016). Recently,
PMCA has been used to study strain adaptation of CWD prions
to a range of cervid host PrPC sequences, suggesting there could
be a constantly evolving diversity of CWD conformers. This has
implications for the potential emergence of CWD in new Cervid
species (Duque Velasquez et al., 2020) that may in turn pose a
threat to human health.
Protein misfolding cyclic amplification has been used to
assess the molecular compatibility and the direct zoonotic
threat that CWD might pose to humans. Barria et al., 2011
reported that CWD PrPSc from mule deer (Odocoileus hemionus)
could convert human PrP from TgHu substrate to produce
PrPSc with a unique molecular profile, contrasting to the
observations reported by Kurt et al. (2009, 2015) of a significant
species barrier between humans and cervids; However, extensive
in vitro conditioning of the mule deer CWD isolate (using
cervid PrPC substrate in PMCA or serial transmission in a
cervidised transgenic mouse model) was necessary to overcome
the molecular barrier and support the conversion of the human
PrPC (Kurt et al., 2009, 2015; Barria et al., 2011).
In a later study, Barria et al., 2014a used PMCA to address
the possibility of direct zoonotic transmission of prions from
cervids to humans, and compared the results with scrapie and
BSE prions. Using PrPC substrate from human, TgHu mouse
brain and 293F cultured cells, we showed that CWD PrPSc from
North American elk (Cervus canadensis) could convert PrPC,
albeit less efficiently than BSE (Barria et al., 2014a). This study
concluded that there were no absolute molecular barriers for
CWD to infect humans.
In addition, the zoonotic potential of CWD was further
examined by testing prion seeds from North American elk of
different cervid PRNP codon 132 genotypes and wild-tailed
deer (O. virginianus), against TgHu substrate in a single-round
PMCA. All cervid seeds induced conversion of human PrPC,
although conversion efficiency depended on the compatibility of
Frontiers in Aging Neuroscience | www.frontiersin.org 9 August 2021 | Volume 13 | Article 716452
fnagi-13-716452 July 28, 2021 Time: 13:35 # 10
Peden et al. Understanding Intra-Species and Inter-Species Prion Conversion
the codon 132 genotype of cervid PrP and the corresponding
codon 129 of human PRNP (Barria et al., 2018b).
Zoonotic Threat of Atypical Animal Prions
Atypical scrapie, also known as Nor98, is a rare prion disease
of sheep identified as a result of active surveillance for scrapie
(Benestad et al., 2003). In PMCA investigations of its zoonotic
potential, Nor98 failed to induce significant conversion using
PrPC substrate from human, TgHu mouse brain and 293 F
cultured cells in contrast to BSE and human CJD positive controls
(Barria et al., 2014a).
Atypical BSE is a rare, atypical prion disease of cattle
comprising two forms: L-type BSE and H-type BSE. L-type BSE,
also known as bovine amyloidotic spongiform encephalopathy,
is neuropathologically characterized by amyloid plaques in
the brain, and has a PrPSc subtype similar to type 2A in
human sCJD patients, with a faster migrating unglycosylated
fragment compared with C-type BSE (Casalone et al., 2004).
The other atypical form, H-type BSE, is characterized by a
slower migrating protease resistant PrPSc fragments compared
with C-type BSE (Biacabe et al., 2004). In contrast to C-type
BSE which is acquired, L-type and H-type BSE are believed to
be sporadic.
Protein misfolding cyclic amplification was used to assess the
potential for atypical BSE to cross the species barrier to humans.
Neither L-type nor H-type BSE induced significant conversion in
PMCA using PrPC substrate from human, TgHu mouse brain
and 293 F cultured cells (Barria et al., 2014a,b), in contrast to
C-type BSE and human CJD positive controls (Barria et al.,
2014a). This could be taken to suggest that the atypical forms of
BSE pose a poor zoonotic threat, or are far less likely to transmit
to humans compared to classic BSE. However, an earlier finding
reported that L-type BSE was able to produce infectivity in a
humanized transgenic mice model overexpressing the human
prion protein (Beringue et al., 2008).
Zoonotic Threat of CWD Emerging in Europe
The first identification of CWD in Europe occurred in 2016
in wild moose (Acles alces, also known as Eurasian elk) and
in a free-ranging reindeer (Rangifer tarandus, closely related
to the free-ranging caribou of North America), a species not
previously known to be affected by CWD in wild or farmed
animals (Benestad et al., 2016). The molecular compatibility
and zoonotic potential of CWD in reindeer was examined by
testing prion seeds from two reindeer experimentally infected
with CWD from white-tailed deer (Mitchell et al., 2012).
Seeds prepared from these reindeer brains were tested against
TgHuMM, TgHuMV, TgHuVV substrates in a single-round
PMCA (Barria et al., 2018b). This study again used the 3F4
monoclonal antibody to detect the induced conversion of human
PrPC to protease resistant PrPSc. Samples of PrPSc from one of
the two CWD infected reindeer could induce robust conversion
of MM, MV, and VV substrates. The other reindeer had a
lower abundance of PrPSc and showed weaker conversion of
all three substrate genotypes tested. Barria et al., 2018b showed
that low levels of experimentally infected reindeer brain PrPSc
could be partially purified and normalized (according to the
level of protease-resistant PrPSc) and used to successfully seed
PMCA reactions. The influence of codon 129 on the molecular
barriers for conversion of human PrPC by reindeer PrPSc
is currently being further investigated. Consistent with our
previous findings and those reported previously by Raymond
et al. (1997, 2000) and (Barria et al., 2011, 2014a,b, 2018b),
we concluded that there were no absolute molecular barriers
to the conversion of human PrPC by CWD PrPSc, and a
more comprehensive and thorough assessment of the zoonotic
potential of CWD might be needed.
Investigating the Potential of CWD to
Infect Other Non-human Species
The above PMCA studies involved comparing seeds from
multiple species against substrate from one species, namely
humans. An alternative approach is to test one seed on substrates
from multiple species. For example, this approach can be used
to assess the threat posed by CWD infected cervids to other
species that share its environment in the wild. Furthermore, PrP
sequence alignment can be used to assess the key determinants
of the species barrier. Kurt et al., 2009 used saPMCA to show
that vole and field mouse PrPC supported serial amplification of
white tailed deer (WTD) CWD PrPSc, whereas prairie dog and
coyote PrPC did not. Sequence comparisons of multiple species
substrates showed that asparagine at codon 170 of the substrate
PrPC was important for supporting trans-species conversion
(Kurt et al., 2009).
The potential for cross transmission of prion disease between
cervids and sheep has been investigated using another version of
the PMCA concept, namely recPMCA (Figure 4). This method
is a variation of saPMCA that focuses on the effect of PrP
sequence differences on molecular compatibility (Erana et al.,
2017; Fernandez-Borges et al., 2017). When recPMCA is used
to investigate species barriers, the seeds from the species of
origin are firstly amplified in multiple rounds of PMCA using
bacterially expressed recombinant PrP (recPrP) of the same
species. Although unglycosylated, it is assumed that the recPrPSc
end products retain some of the conformational properties of the
original seed. The levels of the recPrPSc seeds are normalized,
before being serial diluted and used to seed PMCA reactions
containing wild-type or mutant recPrP from one or more target
species (Erana et al., 2017; Harrathi et al., 2019). The advantage
of using recPrP as a substrate is that mutant forms can be readily
engineered to investigate the effects of amino acid substitutions,
deletions, or insertions.
Using recPMCA Harrathi et al. (2019) were unable to serially
convert wild-type sheep recPrP substrate using CWD recPrPSc,
indicating a significant species barrier for the transmission
of CWD to sheep. However, single residue substitutions at
four sites in ovine PrP affected its potential to be converted
by CWD recPrPSc, which offered insights into PrP sequence-
structure factors affecting the potential for cross-infection from
cervids to sheep, such as the β2-α2 loop (Harrathi et al.,
2019). It should be noted that transmission studies where
sheep have been challenged with mule deer CWD, and elk
challenged with sheep scrapie, suggest that the species barrier
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FIGURE 4 | Recombinant PMCA (recPMCA). In recPMCA, bacterially expressed and purified recombinant PrP (recPrP) is used as a substrate for conversion. Firstly,
PrPSc from infected tissue of the species of origin (dark green) is propagated by saPMCA using recPrP from the same species to produce recPrPSc as an end
product, detectable on western blots as a single band. Propagation in recPMCA requires the presence of “helper” brain homogenate from PRNP–/– animals. Thus,
the effects of variable PrPC expression, glycosylation and cofactors that affect conventional PMCA reactions are largely eliminated, to focus primarily on the effect of
sequence and conformational compatibility. The levels of recPrPSc are normalized and the recPrPSc is serially diluted in recPrP from the target species before being
subjected to cycles of sonication and incubation. Species barriers are assessed according to how abruptly PMCA conversion is diminished by serial dilution of the
seed: i.e., if the barrier is low, highly diluted seed will still cause conversion. Mutant forms of recPrP can easily be generated to examine the effect of amino acid
substitutions on species barriers.
between sheep and cervids is not absolute (Hamir et al., 2004;
Cassmann et al., 2021).
Advantages and Limitations of saPMCA
for Assessing Zoonotic Potential
For prion diseases, some of the factors linked to the species
barrier phenomenon include (1) differences between the
PRNP sequences of the species (2) the animal prion strain,
as enciphered in the conformation of PrPSc, and (3) the
physiological differences between humans and the animal in
question. The effect of cofactors on prion conversion and the
glycosylation of PrPC are two other species-specific phenomena
that contribute to the species barrier. PMCA can model aspects
associated with the molecular and subcellular compatibility of
the PrPSc structure and PrP sequence, previously referred to
as the “sequence – structure barrier” (Baskakov, 2014). Although
PMCA may be limited in its ability to model additional
factors operating above the subcellular level, it provides a
powerful method for investigating the features affecting the
molecular compatibility between heterologous PrPSc and PrPC
that are still not fully understood. The fact that PMCA
produces bona fide PrPSc as an end product means that
PMCA can help to indicate the molecular profile that may
arise from a cross-species infection. The properties of the
PrPSc end product can be assessed, such as the western
blot profile, or its equilibrium dissociation curve following
denaturation with increasing concentrations of guanidine
HCl (Yokoyama et al., 2011). Furthermore, this product can
be used in onward animal transmission studies, to obtain
additional strain characteristics including clinical signs, the
neuroanatomical distribution of lesions and PrPSc deposition and
incubation periods (Beck et al., 2013).
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A practical advantage of PMCA for modeling species barriers
is speed. A single round of PMCA typically takes 48 h, although
multiple rounds of saPMCA may take several weeks. However,
this is considerably shorter that the months or years taken to
complete animal transmission studies.
An important consideration in PMCA is ensuring the
availability and consistency of the substrate. Conversion is most
efficient and reliable using perfused brain from experimental
animals, usually transgenic mice. For assessing the zoonotic
threat to humans, post-mortem human brain tissue with consent
for use can be used, but there are factors that confound
conversion efficiency and consistency, including post mortem
interval, the presence of blood, and variability between samples
in terms of the relative content of gray and white matter. To
improve consistency, the use of a stably transfected human cell
cultures as a source of human PrPC substrate for PMCA has been
demonstrated (Yokoyama et al., 2011; Barria et al., 2014a,b).
The drive toward more efficient PMCA can have its own
counterpoint. Some particular observations suggest we should
be cautious when modeling species or genotypic barriers
with PMCA. For instance, Vidal et al. (2013) were able to
amplify BSE PrPSc by saPMCA using PrPC from rabbits and
dogs, even though the latter species are considered resistant
to prion disease. Lacroux et al. (2014) have developed a
PMCA assay using ovine Q171 substrate which can efficiently
amplify BSE/vCJD prions regardless of the species of origin.
Therefore, with their methodology, PrP sequence homology
between seed and substrate does not appear to be crucial for
BSE/vCJD prion replication in vitro (Lacroux et al., 2014). It
has also been shown that unseeded saPMCA using leporid
PrPC substrate could lead to the de novo formation of PrPSc,
which could induce disease when used to inoculate rabbits
(Chianini et al., 2012). This suggests that increases in the
efficiency of PMCA can circumvent species barriers, and
induce disease in species that were thought to be resistant,
and therefore careful interpretation of the results of PMCA
experiments is required.
Even when a prion strain is known to be zoonotic, PMCA
could potentially underestimate the species barrier. For instance,
several PMCA studies have shown that human PrPC (M at
codon 129) is readily converted by BSE PrPSc in a manner
dependent upon the genotype at PRNP codon 129 (Raymond
et al., 1997; Jones et al., 2009; Barria et al., 2014a; Krejciova
et al., 2014). However, animal transmission studies pointed to a
higher transmission barrier for BSE between cattle and humans.
Transmission of cattle BSE to TgHu mice overexpressing human
PrPC has been shown to be inefficient (Asante et al., 2002; Padilla
et al., 2011), and no transmission of cattle BSE was observed using
an alternative gene-targeted TgHu mouse model (Bishop et al.,
2006). It should be noted that the extent of the vCJD epidemic
was relatively small compared with the very high numbers cattle
that were infected with BSE. Therefore, the complementation
of in vitro and in vivo models are important to understand
the complexity surrounding species barrier and the zoonotic
potential to humans.
CONCLUSION
Where as animal transmission studies are an effective means
for investigating species barriers, PMCA continues to provide a
time- and cost-efficient alternative that can offer genuine insights
into the molecular feasibility of cross-species transmission, and
some of the strain properties of PrPSc that may arise. PMCA can
be used to assess whether prion strains can transcend species
barriers, and also genotypic barriers within the same species.
Unlike other in vitro conversion assays, PMCA can predict
alterations in the molecular profile of PrPSc that might occur
upon adaptation to a new species. PMCA can also uncover
evidence of traceback, a give indications on the likely origin
of a prion strain. Also, PMCA, using substrate from the target
species, can be used to model the molecular compatibility and
zoonotic risk of the prion agent. In summary, the PMCA
group of techniques provide a powerful approach for assessing
intra- and inter-species barriers, focused on the molecular
feasibility of prion conversion. However, the results should be
interpreted with caution, and can be complemented with animal
transmission and epidemiological studies in circumstances where
they are available.
AUTHOR CONTRIBUTIONS
AP, SS, and MB: writing—original draft preparation, review and
editing. MB: conceptualization. All authors: read and agreed to
the published version of the manuscript.
FUNDING
This report is independent research commissioned and funded
by the Department of Health and Social Care Policy Research
Programme and the Government of Scotland [“The National
CJD Research and Surveillance Unit (NCJDRSU),” PR-ST-0614-
00008_18].
ACKNOWLEDGMENTS
The authors wish to thank Fraser Brydon for his valuable
time in proofreading this review. All figures were created with
BioRender package.
REFERENCES
Asante, E. A., Linehan, J. M., Desbruslais, M., Joiner, S., Gowland, I.,
Wood, A. L., et al. (2002). BSE prions propagate as either variant CJD-
like or sporadic CJD-like prion strains in transgenic mice expressing
human prion protein. Embo J. 21, 6358–6366. doi: 10.1093/emboj/
cdf653
Babelhadj, B., Di Bari, M. A., Pirisinu, L., Chiappini, B., Gaouar, S. B. S., Riccardi,
G., et al. (2018). Prion disease in dromedary camels, Algeria. Emerg. Infect. Dis.
24, 1029–1036. doi: 10.3201/eid2406.172007
Frontiers in Aging Neuroscience | www.frontiersin.org 12 August 2021 | Volume 13 | Article 716452
fnagi-13-716452 July 28, 2021 Time: 13:35 # 13
Peden et al. Understanding Intra-Species and Inter-Species Prion Conversion
Barria, M. A., Balachandran, A., Morita, M., Kitamoto, T., Barron, R., Manson,
J., et al. (2014a). Molecular barriers to zoonotic transmission of prions. Emerg.
Infect. Dis. 20, 88–97. doi: 10.3201/eid2001.130858
Barria, M. A., Ironside, J. W., and Head, M. W. (2014b). Exploring the zoonotic
potential of animal prion diseases: in vivo and in vitro approaches. Prion 8,
85–91. doi: 10.4161/pri.28124
Barria, M. A., Lee, A., Green, A. J., Knight, R., and Head, M. W. (2018a). Rapid
amplification of prions from variant Creutzfeldt-Jakob disease cerebrospinal
fluid. J. Pathol. Clin. Res. 4, 86–92. doi: 10.1002/cjp2.90
Barria, M. A., Libori, A., Mitchell, G., and Head, M. W. (2018b). Susceptibility of
human prion protein to conversion by chronic wasting disease Prions. Emerg.
Infect. Dis. 24, 1482–1489. doi: 10.3201/eid2408.161888
Barria, M. A., Telling, G. C., Gambetti, P., Mastrianni, J. A., and Soto, C.
(2011). Generation of a new form of human PrP(Sc) in vitro by interspecies
transmission from cervid prions. J. Biol. Chem. 286, 7490–7495. doi: 10.1074/
jbc.m110.198465
Baskakov, I. V. (2014). The many shades of prion strain adaptation. Prion 8,
169–172. doi: 10.4161/pri.27836
Beck, K. E., Thorne, L., Lockey, R., Vickery, C. M., Terry, L. A., Bujdoso, R., et al.
(2013). Strain typing of classical scrapie by transgenic mouse bioassay using
protein misfolding cyclic amplification to replace primary passage. PLoS One
8:e57851. doi: 10.1371/journal.pone.0057851
Bellworthy, S. J., Dexter, G., Stack, M., Chaplin, M., Hawkins, S. A., Simmons,
M. M., et al. (2005). Natural transmission of BSE between sheep within an
experimental flock. Vet. Rec. 157:206. doi: 10.1136/vr.157.7.206
Benestad, S. L., Mitchell, G., Simmons, M., Ytrehus, B., and Vikoren, T. (2016). First
case of chronic wasting disease in Europe in a Norwegian free-ranging reindeer.
Vet. Res. 47:88.
Benestad, S. L., Sarradin, P., Thu, B., Schonheit, J., Tranulis, M. A., and Bratberg,
B. (2003). Cases of scrapie with unusual features in Norway and designation of
a new type, Nor98. Vet. Rec. 153, 202–208. doi: 10.1136/vr.153.7.202
Beringue, V., Herzog, L., Reine, F., Le Dur, A., Casalone, C., Vilotte, J. L., et al.
(2008). Transmission of atypical bovine prions to mice transgenic for human
prion protein. Emerg. Infect. Dis. 14, 1898–1901. doi: 10.3201/eid1412.080941
Bernoulli, C., Siegfried, J., Baumgartner, G., Regli, F., Rabinowicz, T., Gajdusek,
D. C., et al. (1977). Danger of accidental person-to-person transmission of
Creutzfeldt-Jakob disease by surgery. Lancet 1, 478–479. doi: 10.1016/s0140-
6736(77)91958-4
Biacabe, A. G., Laplanche, J. L., Ryder, S., and Baron, T. (2004). Distinct molecular
phenotypes in bovine prion diseases. EMBO Rep. 5, 110–115. doi: 10.1038/sj.
embor.7400054
Bishop, M. T., Hart, P., Aitchison, L., Baybutt, H. N., Plinston, C., Thomson, V.,
et al. (2006). Predicting susceptibility and incubation time of human-to-human
transmission of vCJD. Lancet Neurol. 5, 393–398. doi: 10.1016/s1474-4422(06)
70413-6
Bishop, M. T., Will, R. G., and Manson, J. C. (2010). Defining sporadic Creutzfeldt-
Jakob disease strains and their transmission properties. Proc. Natl. Acad. Sci.
U.S.A. 107, 12005–12010. doi: 10.1073/pnas.1004688107
Bougard, D., Belondrade, M., Mayran, C., Bruyere-Ostells, L., Lehmann, S.,
Fournier-Wirth, C., et al. (2018). Diagnosis of methionine/valine variant
creutzfeldt-jakob disease by Protein misfolding cyclic amplification. Emerg.
Infect. Dis. 24, 1364–1366. doi: 10.3201/eid2407.172105
Bougard, D., Brandel, J. P., Belondrade, M., Beringue, V., Segarra, C., Fleury,
H., et al. (2016). Detection of prions in the plasma of presymptomatic and
symptomatic patients with variant Creutzfeldt-Jakob disease. Sci. Transl. Med.
8:370ra182. doi: 10.1126/scitranslmed.aag1257
Brandel, J. P., Preece, M., Brown, P., Croes, E., Laplanche, J. L., Agid, Y., et al.
(2003). Distribution of codon 129 genotype in human growth hormone-treated
CJD patients in France and the UK. Lancet 362, 128–130. doi: 10.1016/s0140-
6736(03)13867-6
Brandner, S., and Jaunmuktane, Z. (2017). Prion disease: experimental models and
reality. Acta Neuropathol. 133, 197–222. doi: 10.1007/s00401-017-1670-5
Brown, P. (1998). Transmission of spongiform encephalopathy through biological
products. Dev. Biol. Stand. 93, 73–78.
Brown, P., Brandel, J. P., Sato, T., Nakamura, Y., MacKenzie, J., Will, R. G., et al.
(2012). Iatrogenic Creutzfeldt-Jakob disease, final assessment. Emerg. Infect.
Dis. 18, 901–907.
Brown, P., Cathala, F., Raubertas, R. F., Gajdusek, D. C., and Castaigne, P.
(1987). The epidemiology of Creutzfeldt-Jakob disease: conclusion of a 15-
year investigation in France and review of the world literature. Neurology 37,
895–904. doi: 10.1212/wnl.37.6.895
Bruce, M. E., Will, R. G., Ironside, J. W., McConnell, I., Drummond, D., Suttie, A.,
et al. (1997). Transmissions to mice indicate that ’new variant’ CJD is caused by
the BSE agent. Nature 389, 498–501. doi: 10.1038/39057
Cali, I., Castellani, R., Alshekhlee, A., Cohen, Y., Blevins, J., Yuan, J., et al. (2009).
Co-existence of scrapie prion protein types 1 and 2 in sporadic Creutzfeldt-
Jakob disease: its effect on the phenotype and prion-type characteristics. Brain
132, 2643–2658. doi: 10.1093/brain/awp196
Cali, I., Lavrich, J., Moda, F., Kofskey, D., Nemani, S. K., Appleby, B., et al. (2019).
PMCA-replicated PrP(D) in urine of vCJD patients maintains infectivity and
strain characteristics of brain PrP(D): transmission study. Sci. Rep. 9:5191.
Casalone, C., Zanusso, G., Acutis, P., Ferrari, S., Capucci, L., Tagliavini,
F., et al. (2004). ’Identification of a second bovine amyloidotic
spongiform encephalopathy: molecular similarities with sporadic
Creutzfeldt-Jakob disease’. Proc. Natl. Acad. Sci. U.S.A. 101, 3065–3070.
doi: 10.1073/pnas.0305777101
Cassmann, E. D., Frese, R. D., and Greenlee, J. J. (2021). Second passage of
chronic wasting disease of mule deer to sheep by intracranial inoculation
compared to classical scrapie. J. Vet. Diagn. Invest. 33, 711–720. doi: 10.1177/
10406387211017615
Castilla, J., Gonzalez-Romero, D., Saá, P., Morales, R., De Castro, J., and Soto, C.
(2008a). Crossing the species barrier by PrPSc replication in vitro generates
unique infectious prions. Cell 134, 757–768. doi: 10.1016/j.cell.2008.07.030
Castilla, J., Morales, R., Saa, P., Barria, M., Gambetti, P., and Soto, C. (2008b). Cell-
free propagation of prion strains. EMBO J. 27, 2557–2566. doi: 10.1038/emboj.
2008.181
Castilla, J., Saa, P., Hetz, C., and Soto, C. (2005). In vitro generation of infectious
scrapie prions. Cell 121, 195–206. doi: 10.1016/j.cell.2005.02.011
Castilla, J., Saa, P., Morales, R., Abid, K., Maundrell, K., and Soto, C. (2006). Protein
misfolding cyclic amplification for diagnosis and prion propagation studies.
Methods Enzymol. 412, 3–21. doi: 10.1016/s0076-6879(06)12001-7
Chianini, F., Fernandez-Borges, N., Vidal, E., Gibbard, L., Pintado, B., de Castro, J.,
et al. (2012). Rabbits are not resistant to prion infection. Proc. Natl. Acad. Sci.
U.S.A. 109, 5080–5085.
Collinge, J. (2016). Mammalian prions and their wider relevance in
neurodegenerative diseases. Nature 539, 217–226. doi: 10.1038/nature2415
Collinge, J., and Clarke, A. R. (2007). A general model of prion strains and their
pathogenicity. Science 318, 930–936. doi: 10.1126/science.1138718
Concha-Marambio, L., Chacon, M. A., and Soto, C. (2020). Preclinical detection of
prions in blood of nonhuman primates infected with variant creutzfeldt-jakob
disease. Emerg. Infect. Dis. 26, 34–43. doi: 10.3201/eid2601.181423
Concha-Marambio, L., Pritzkow, S., Moda, F., Tagliavini, F., Ironside, J. W., Schulz,
P. E., et al. (2016). Detection of prions in blood from patients with variant
Creutzfeldt-Jakob disease. Sci. Transl. Med. 8:370ra183.
Delisle, M. B., Fabre, N., Rochiccioli, P., Doerr-Schott, J., Rumeau, J. L., and Bes, A.
(1993). [Creutzfeldt-Jakob disease after treatment with human extracted growth
hormone. A clinicopathological study]. Rev. Neurol. (Paris) 149, 524–527.
Deslys, J. P., Jaegly, A., d’Aignaux, J. H., Mouthon, F., de Villemeur, T. B., and
Dormont, D. (1998). Genotype at codon 129 and susceptibility to Creutzfeldt-
Jakob disease. Lancet 351:1251. doi: 10.1016/s0140-6736(05)79317-x
Duffy, P., Wolf, J., Collins, G., DeVoe, A. G., Streeten, B., and Cowen, D. (1974).
Letter: possible person-to-person transmission of Creutzfeldt-Jakob disease.
N. Engl. J. Med. 290, 692–693. doi: 10.1056/nejm197403212901220
Duque Velasquez, C., Kim, C., Haldiman, T., Kim, C., Herbst, A., Aiken, J.,
et al. (2020). Chronic wasting disease (CWD) prion strains evolve via adaptive
diversification of conformers in hosts expressing prion protein polymorphisms.
J. Biol. Chem. 295, 4985–5001. doi: 10.1074/jbc.ra120.012546
Erana, H., Fernandez-Borges, N., Elezgarai, S. R., Harrathi, C., Charco, J. M.,
Chianini, F., et al. (2017). In vitro approach to identify key amino acids in low
susceptibility of rabbit prion protein to misfolding. J. Virol. 91, e1543–e1517.
Espinosa, J. C., Andreoletti, O., Castilla, J., Herva, M. E., Morales, M., Alamillo, E.,
et al. (2007). Sheep-passaged bovine spongiform encephalopathy agent exhibits
altered pathobiological properties in bovine-PrP transgenic mice. J. Virol. 81,
835–843. doi: 10.1128/jvi.01356-06
Frontiers in Aging Neuroscience | www.frontiersin.org 13 August 2021 | Volume 13 | Article 716452
fnagi-13-716452 July 28, 2021 Time: 13:35 # 14
Peden et al. Understanding Intra-Species and Inter-Species Prion Conversion
Fernandez-Borges, N., Erana, H., Elezgarai, S. R., Harrathi, C., Venegas, V., and
Castilla, J. (2017). A quick method to evaluate the effect of the amino acid
sequence in the misfolding proneness of the Prion protein. Methods Mol. Biol.
1658, 205–216. doi: 10.1007/978-1-4939-7244-9_15
Foster, J. D., Parnham, D., Chong, A., Goldmann, W., and Hunter, N. (2001).
Clinical signs, histopathology and genetics of experimental transmission of BSE
and natural scrapie to sheep and goats. Vet. Rec. 148, 165–171. doi: 10.1136/vr.
148.6.165
Gibbs, C. J. Jr., Joy, A., Heffner, R., Franko, M., Miyazaki, M., Asher, D. M.,
et al. (1985). Clinical and pathological features and laboratory confirmation
of Creutzfeldt-Jakob disease in a recipient of pituitary-derived human growth
hormone. N. Engl. J. Med. 313, 734–738. doi: 10.1056/nejm198509193131207
Goldmann, W. (2008). PrP genetics in ruminant transmissible spongiform
encephalopathies. Vet. Res. 39:30. doi: 10.1051/vetres:2008010
Gonzalez, L., Jeffrey, M., Dagleish, M. P., Goldmann, W., Siso, S., Eaton, S. L.,
et al. (2012). Susceptibility to scrapie and disease phenotype in sheep: cross-
PRNP genotype experimental transmissions with natural sources. Vet. Res.
43:55. doi: 10.1186/1297-9716-43-55
Gonzalez, L., Martin, S., and Jeffrey, M. (2003). Distinct profiles of PrP(d)
immunoreactivity in the brain of scrapie- and BSE-infected sheep: implications
for differential cell targeting and PrP processing. J. Gen. Virol. 84, 1339–1350.
doi: 10.1099/vir.0.18800-0
Green, K. M., Castilla, J., Seward, T. S., Napier, D. L., Jewell, J. E., Soto, C., et al.
(2008). Accelerated high fidelity prion amplification within and across prion
species barriers. PLoS Pathog. 4:e1000139. doi: 10.1371/journal.ppat.1000139
Greenlee, J. J. (2019). Review: update on classical and atypical scrapie in sheep and
goats. Vet. Pathol. 56, 6–16. doi: 10.1177/0300985818794247
Griffith, J. S. (1967). Self-replication and scrapie. Nature 215, 1043–1044. doi:
10.1038/2151043a0
Halliez, S., Passet, B., Martin-Lannerée, S., Hernandez-Rapp, J., Laude, H.,
Mouillet-Richard, S., et al. (2014). To develop with or without the prion protein.
Front. Cell Dev. Biol. 2:58. doi: 10.3389/fcell.2014.00058
Hamir, A. N., Miller, J. M., Cutlip, R. C., Kunkle, R. A., Jenny, A. L., Stack, M. J.,
et al. (2004). Transmission of sheep scrapie to elk (Cervus elaphus nelsoni) by
intracerebral inoculation: final outcome of the experiment. J. Vet. Diagn. Invest.
16, 316–321. doi: 10.1177/104063870401600410
Harrathi, C., Fernandez-Borges, N., Erana, H., Elezgarai, S. R., Venegas, V., Charco,
J. M., et al. (2019). Insights into the bidirectional properties of the sheep-
deer prion transmission barrier. Mol. Neurobiol. 56, 5287–5303. doi: 10.1007/
s12035-018-1443-8
Head, M. W., and Ironside, J. W. (2012). Review: creutzfeldt-Jakob disease: prion
protein type, disease phenotype and agent strain. Neuropathol. Appl. Neurobiol.
38, 296–310. doi: 10.1111/j.1365-2990.2012.01265.x
Hill, A. F., Desbruslais, M., Joiner, S., Sidle, K. C., Gowland, I., Collinge, J., et al.
(1997). The same prion strain causes vCJD and BSE. Nature 389, 448–450. 526.
doi: 10.1038/38925
Hope, J. (2013). Bovine spongiform encephalopathy: a tipping point in One Health
and Food Safety. Curr. Top. Microbiol. Immunol. 366, 37–47. doi: 10.1007/978-
3-662-45791-7_264
Hunter, N., and Bossers, A. (2006). Prions in Humans and Animals, eds B.
Hörnlimann, D. Riesner, H. Kretzschmar (Berlin: de Gruyter), 640–647.
Huor, A., Espinosa, J. C., Vidal, E., Cassard, H., Douet, J. Y., Lugan, S., et al. (2019).
The emergence of classical BSE from atypical/Nor98 scrapie. Proc. Natl. Acad.
Sci. U.S.A. 116, 26853–26862. doi: 10.1073/pnas.1915737116
Igel-Egalon, A., Béringue, V., Rezaei, H., and Sibille, P. (2018). Prion strains and
transmission barrier Phenomena. Pathogens (Basel, Switzerland) 7:5. doi: 10.
3390/pathogens7010005
Ironside, J. W., Ritchie, D. L., Peden, A. H., and Head, M. W. (2014). “Human prion
diseases,” in Neuropathology of Neurodegenerative Diseases: A Practical Guide,
ed. G. G. Kovacs (Cambridge: Cambridge University Press).
Jeffrey, M., Martin, S., Gonzalez, L., Ryder, S. J., Bellworthy, S. J., and Jackman,
R. (2001). Differential diagnosis of infections with the bovine spongiform
encephalopathy (BSE) and scrapie agents in sheep. J. Comp. Pathol. 125,
271–284. doi: 10.1053/jcpa.2001.0499
Jeffrey, M., Witz, J. P., Martin, S., Hawkins, S. A., Bellworthy, S. J., Dexter, G. E.,
et al. (2015). Dynamics of the natural transmission of bovine spongiform
encephalopathy within an intensively managed sheep flock. Vet. Res. 46:126.
Joiner, S., Asante, E. A., Linehan, J. M., Brock, L., Brandner, S., Bellworthy, S. J., et al.
(2018). Experimental sheep BSE prions generate the vCJD phenotype when
serially passaged in transgenic mice expressing human prion protein. J. Neurol.
Sci. 386, 4–11. doi: 10.1016/j.jns.2017.12.038
Jones, M., Peden, A. H., Prowse, C. V., Gröner, A., Manson, J. C., Turner, M. L.,
et al. (2007). In vitro amplification and detection of variant Creutzfeldt-Jakob
disease PrPSc. J. Pathol. 213, 21–26. doi: 10.1002/path.2204
Jones, M., Peden, A. H., Wight, D., Prowse, C., MacGregor, I., Manson, J.,
et al. (2008). Effects of human PrPSc type and PRNP genotype in an
in-vitro conversion assay. NeuroReport 19, 1783–1786. doi: 10.1097/wnr.
0b013e328318edfa
Jones, M., Wight, D., Barron, R., Jeffrey, M., Manson, J., Prowse, C., et al. (2009).
Molecular model of prion transmission to humans. Emerg. Infect. Dis. 15,
2013–2016. doi: 10.3201/eid1512.090194
Kobayashi, A., Asano, M., Mohri, S., and Kitamoto, T. (2007). Cross-sequence
transmission of sporadic creutzfeldt-jakob disease creates a new Prion Strain.
J. Biol. Chem. 282, 30022–30028. doi: 10.1074/jbc.m704597200
Kobayashi, A., Asano, M., Mohri, S., and Kitamoto, T. (2009). A traceback
phenomenon can reveal the origin of prion infection. Neuropathology 29,
619–624. doi: 10.1111/j.1440-1789.2008.00973.x
Kobayashi, A., Parchi, P., Yamada, M., Mohri, S., and Kitamoto, T. (2016).
Neuropathological and biochemical criteria to identify acquired Creutzfeldt-
Jakob disease among presumed sporadic cases. Neuropathology 36, 305–310.
doi: 10.1111/neup.12270
Kobayashi, A., Sakuma, N., Matsuura, Y., Mohri, S., Aguzzi, A., and Kitamoto,
T. (2010). Experimental verification of a traceback phenomenon in prion
infection. J. Virol. 84, 3230–3238. doi: 10.1128/jvi.02387-09
Koch, T. K., Berg, B. O., De Armond, S. J., and Gravina, R. F. (1985). Creutzfeldt-
Jakob disease in a young adult with idiopathic hypopituitarism. Possible relation
to the administration of cadaveric human growth hormone. N. Engl. J. Med. 313,
731–733. doi: 10.1056/nejm198509193131206
Kocisko, D. A., Come, J. H., Priola, S. A., Chesebro, B., Raymond, G. J., Lansbury,
P. T., et al. (1994). Cell-free formation of protease-resistant prion protein.
Nature 370, 471–474. doi: 10.1038/370471a0
Krejciova, Z., Barria, M., Jones, M., Ironside, J., Jeffrey, M., Gonzalez, L., et al.
(2014). Genotype-dependent molecular evolution of sheep BSE Prions in vitro
affects their zoonotic potential. J. Biol. Chem. 289, 26075–26088. doi: 10.1074/
jbc.m114.582965
Kurt, T. D., Jiang, L., Fernandez-Borges, N., Bett, C., Liu, J., Yang, T., et al. (2015).
Human prion protein sequence elements impede cross-species chronic wasting
disease transmission. J. Clin. Invest. 125:2548. doi: 10.1172/jci82647
Kurt, T. D., Telling, G. C., Zabel, M. D., and Hoover, E. A. (2009). Trans-species
amplification of PrP(CWD) and correlation with rigid loop 170N. Virology 387,
235–243. doi: 10.1016/j.virol.2009.02.025
Lacroux, C., Comoy, E., Moudjou, M., Perret-Liaudet, A., Lugan, S., Litaise, C.,
et al. (2014). Preclinical detection of variant CJD and BSE prions in blood. PLoS
Pathogens 10:e1004202. doi: 10.1371/journal.ppat.1004202
Levavasseur, E., Privat, N., Martin, J. C. E., Simoneau, S., Baron, T., Flan, B.,
et al. (2014). Molecular modeling of prion transmission to humans. Viruses 6,
3766–3777. doi: 10.3390/v6103766
Love, S., Budka, H., Ironside, J. W., and Perry, A. (2015). Greenfield’s
Neuropathology Vols 1 and 2, Volume 2: VII-VIII∗, 9th Edn, Vol. 2. Boca Raton,
London, New York: CRC Press, Taylor and Frances Group.
Makarava, N., and Baskakov, I. V. (2012). Genesis of tramsmissible protein states
via deformed templating. Prion 6, 252–255. doi: 10.4161/pri.19930
Makarava, N., Savtchenko, R., and Baskakov, I. V. (2013). Selective amplification
of classical and atypical prions using modified protein misfolding cyclic
amplification. J. Biol. Chem. 288, 33–41. doi: 10.1074/jbc.m112.419531
Mitchell, G. B., Sigurdson, C. J., O’Rourke, K. I., Algire, J., Harrington, N. P.,
Walther, I., et al. (2012). Experimental oral transmission of chronic wasting
disease to reindeer (Rangifer tarandus tarandus). PLoS One 7:e39055. doi: 10.
1371/journal.pone.0039055
Moda, F., Gambetti, P., Notari, S., Concha-Marambio, L., Catania, M., Park, K. W.,
et al. (2014). Prions in the urine of patients with variant creutzfeldt–jakob
disease. N. Engl. J. Med. 371, 530–539.
Moda, F., Suardi, S., Di, Fede G., Indaco, A., Limido, L., Vimercati, C., et al. (2012).
MM2-thalamic Creutzfeldt-Jakob disease: neuropathological, biochemical and
Frontiers in Aging Neuroscience | www.frontiersin.org 14 August 2021 | Volume 13 | Article 716452
fnagi-13-716452 July 28, 2021 Time: 13:35 # 15
Peden et al. Understanding Intra-Species and Inter-Species Prion Conversion
transmission studies identify a distinctive prion strain. Brain Pathol. 22, 662–
669. doi: 10.1111/j.1750-3639.2012.00572.x
Mok, T., Jaunmuktane, Z., Joiner, S., Campbell, T., Morgan, C., Wakerley, B., et al.
(2017). Variant Creutzfeldt-Jakob Disease in a Patient with Heterozygosity at
PRNP Codon 129. N. Engl. J. Med. 376, 292–294. doi: 10.1056/nejmc1610003
Padilla, D., Beringue, V., Espinosa, J. C., Andreoletti, O., Jaumain, E., Reine, F.,
et al. (2011). Sheep and goat BSE propagate more efficiently than cattle BSE
in human PrP transgenic mice. PLoS Pathog. 7:e1001319. doi: 10.1371/journal.
ppat.1001319
Palmer, M. S., Dryden, A. J., Hughes, J. T., and Collinge, J. (1991). Homozygous
prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease.
Nature 352, 340–342. doi: 10.1038/352340a0
Parchi, P., De Boni, L., Saverioni, D., Cohen, M. L., Ferrer, I., Gambetti, P.,
et al. (2012). Consensus classification of human prion disease histotypes
allows reliable identification of molecular subtypes: an inter-rater study among
surveillance centres in Europe and USA. Acta Neuropathol. 124, 517–529. doi:
10.1007/s00401-012-1002-8
Parchi, P., Giese, A., Capellari, S., Brown, P., Schulz-Schaeffer, W., Windl, O.,
et al. (1999). Classification of sporadic Creutzfeldt-Jakob disease based on
molecular and phenotypic analysis of 300 subjects. Ann. Neurol. 46, 224–233.
doi: 10.1002/1531-8249(199908)46:2<224::aid-ana12>3.0.co;2-w
Parchi, P., Strammiello, R., Notari, S., Giese, A., Langeveld, J. P., Ladogana, A.,
et al. (2009). Incidence and spectrum of sporadic Creutzfeldt-Jakob disease
variants with mixed phenotype and co-occurrence of PrPSc types: an updated
classification. Acta Neuropathol. 118, 659–671. doi: 10.1007/s00401-009-0585-1
Parchi, P., Zou, W., Wang, W., Brown, P., Capellari, S., Ghetti, B., et al. (2000).
Genetic influence on the structural variations of the abnormal prion protein.
Proc. Natl. Acad. Sci. U.S. A. 97, 10168–10172. doi: 10.1073/pnas.97.18.10168
Peden, A. H., Head, M. W., Ritchie, D. L., Bell, J. E., and Ironside, J. W. (2004).
Preclinical vCJD after blood transfusion in a PRNP codon 129 heterozygous
patient. Lancet 364, 527–529. doi: 10.1016/s0140-6736(04)16811-6
Plinston, C., Hart, P., Hunter, N., Manson, J. C., and Barron, R. M.
(2014). Increased susceptibility of transgenic mice expressing human PrP to
experimental sheep bovine spongiform encephalopathy is not due to increased
agent titre in sheep brain tissue. J. Gen. Virol. 95, 1855–1859. doi: 10.1099/vir.
0.065730-0
Pocchiari, M., Puopolo, M., Croes, E. A., Budka, H., Gelpi, E., Collins, S., et al.
(2004). Predictors of survival in sporadic Creutzfeldt–Jakob disease and other
human transmissible spongiform encephalopathies. Brain 127, 2348–2359. doi:
10.1093/brain/awh249
Polymenidou, M., Stoeck, K., Glatzel, M., Vey, M., Bellon, A., and Aguzzi, A.
(2005). Coexistence of multiple PrPSc types in individuals with Creutzfeldt-
Jakob disease. Lancet Neurol. 4, 805–814. doi: 10.1016/s1474-4422(05)70225-8
Powell-Jackson, J., Weller, R. O., Kennedy, P., Preece, M. A., Whitcombe, E. M.,
and Newsom-Davis, J. (1985). Creutzfeldt-Jakob disease after administration
of human growth hormone. Lancet 2, 244–246. doi: 10.1016/s0140-6736(85)
90292-2
Prusiner, S. B. (1982). Novel proteinaceous infectious particles cause scrapie.
Science 216, 136–144. doi: 10.1126/science.6801762
Raymond, G. J., Bossers, A., Raymond, L. D., O’Rourke, K. I., McHolland, L. E.,
Bryant, P. K. 3rd, et al. (2000). Evidence of a molecular barrier limiting
susceptibility of humans, cattle and sheep to chronic wasting disease. Embo J.
19, 4425–4430. doi: 10.1093/emboj/19.17.4425
Raymond, G. J., Hope, J., Kocisko, D. A., Priola, S. A., Raymond, L. D., Bossers, A.,
et al. (1997). Molecular assessment of the potential transmissibilities of BSE and
scrapie to humans. Nature 388, 285–288. doi: 10.1038/40876
Richt, J. A., and Hall, S. M. (2008). BSE case associated with prion protein gene
mutation. PLoS Pathog. 4:e1000156. doi: 10.1371/journal.ppat.1000156
Ritchie, D. L., and Barria, M. A. (2021). Prion diseases: a unique transmissible
agent or a model for neurodegenerative diseases? Biomolecules 11:207. doi:
10.3390/biom11020207
Ritchie, D. L., Barria, M. A., Peden, A. H., Yull, H. M., Kirkpatrick, J., Adlard,
P., et al. (2017). UK Iatrogenic Creutzfeldt–Jakob disease: investigating human
prion transmission across genotypic barriers using human tissue-based and
molecular approaches. Acta Neuropathol. 133, 579–595. doi: 10.1007/s00401-
016-1638-x
Rudge, P., Jaunmuktane, Z., Adlard, P., Bjurstrom, N., Caine, D., Lowe, J.,
et al. (2015). Iatrogenic CJD due to pituitary-derived growth hormone with
genetically determined incubation times of up to 40 years. Brain 138, 3386–
3399. doi: 10.1093/brain/awv235
Saborio, G. P., Permanne, B., and Soto, C. (2001). Sensitive detection of
pathological prion protein by cyclic amplification of protein misfolding. Nature
411, 810–813. doi: 10.1038/35081095
Sigurdson, C. J., and Aguzzi, A. (2007). Chronic wasting disease. Biochim. Biophys.
Acta 1772, 610–618.
Stack, M., Gonzalez, L., Jeffrey, M., Martin, S., Macaldowie, C., Chaplin, M., et al.
(2009). Three serial passages of bovine spongiform encephalopathy in sheep do
not significantly affect discriminatory test results. J. Gen. Virol. 90, 764–768.
doi: 10.1099/vir.0.005983-0
Stack, M., Jeffrey, M., Gubbins, S., Grimmer, S., Gonzalez, L., Martin, S., et al.
(2006). Monitoring for bovine spongiform encephalopathy in sheep in Great
Britain, 1998-2004. J. Gen. Virol. 87, 2099–2107. doi: 10.1099/vir.0.81254-0
Takeuchi, A., Kobayashi, A., Parchi, P., Yamada, M., Morita, M., Uno, S.,
et al. (2016). Distinctive properties of plaque-type dura mater graft-associated
Creutzfeldt–Jakob disease in cell-protein misfolding cyclic amplification.
Laboratory Invest. 96, 581–587. doi: 10.1038/labinvest.2016.27
Thuring, C. M., Erkens, J. H., Jacobs, J. G., Bossers, A., Van Keulen, L. J., Garssen,
G. J., et al. (2004). Discrimination between scrapie and bovine spongiform
encephalopathy in sheep by molecular size, immunoreactivity, and glycoprofile
of prion protein. J. Clin. Microbiol. 42, 972–980. doi: 10.1128/jcm.42.3.972-980.
2004
Uro-Coste, E., Cassard, H., Simon, S., Lugan, S., Bilheude, J. M., Perret-Liaudet,
A., et al. (2008). Beyond PrP9res) type 1/type 2 dichotomy in Creutzfeldt-Jakob
disease. PLoS Pathog. 4:e1000029. doi: 10.1371/journal.ppat.1000029
Urwin, P. J., Mackenzie, J. M., Llewelyn, C. A., Will, R. G., and Hewitt, P. E. (2016).
Creutzfeldt-Jakob disease and blood transfusion: updated results of the UK
Transfusion Medicine Epidemiology Review Study. Vox. Sang 110, 310–316.
doi: 10.1111/vox.12371
van Duijn, C. M., Delasnerie-Laupretre, N., Masullo, C., Zerr, I., de Silva,
R., Wientjens, D. P., et al. (1998). Case-control study of risk factors of
Creutzfeldt-Jakob disease in Europe during 1993-95. European Union (EU)
Collaborative Study Group of Creutzfeldt-Jakob disease (CJD). Lancet 351,
1081–1085.
Vidal, E., Fernandez-Borges, N., Pintado, B., Ordonez, M., Marquez, M., Fondevila,
D., et al. (2013). Exploring the risks of a putative transmission of BSE to new
species. Prion 7, 443–446. doi: 10.4161/pri.27014
Will, R. G., Ironside, J. W., Zeidler, M., Cousens, S. N., Estibeiro, K., Alperovitch,
A., et al. (1996). A new variant of Creutzfeldt-Jakob disease in the UK. Lancet
347, 921–925.
Will, R. G., and Matthews, W. B. (1982). Evidence for case-to-case transmission
of Creutzfeldt-Jakob disease. J. Neurol. Neurosurg. Psychiatry 45, 235–238. doi:
10.1136/jnnp.45.3.235
Wulf, M. A., Senatore, A., and Aguzzi, A. (2017). The biological function of the
cellular prion protein: an update. BMC Biol. 15:34. doi: 10.1186/s12915-017-
0375-5
Yokoyama, T., Takeuchi, A., Yamamoto, M., Kitamoto, T., Ironside, J. W.,
and Morita, M. (2011). Heparin enhances the cell-protein misfolding cyclic
amplification efficiency of variant Creutzfeldt-Jakob disease. Neurosci. Lett. 498,
119–123. doi: 10.1016/j.neulet.2011.04.072
Author Disclaimer: The views expressed in this publication are those of the
author(s) and not necessarily those of the Department of Health and Social Care
or the Government of Scotland.
Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Peden, Suleiman and Barria. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) and the copyright owner(s) are credited and that the original
publication in this journal is cited, in accordance with accepted academic practice. No
use, distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Aging Neuroscience | www.frontiersin.org 15 August 2021 | Volume 13 | Article 716452
